




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



## Letter to Editors

## Purposing Saikosaponins for the treatment of COVID-19

Till the moment, there are no approved antiviral treatments for COVID-19. Saikosaponin A, Saikosaponin B, and Saikosaponin D are major triterpenoid saponins derived from *Bupleurum falcatum* L. (*Umbelliferae*) with valuable pharmacological activities. These active components exhibit several immunomodulatory, anti-inflammatory, anti-bacterial, antiviral, and anti-cancer effects. We propose that Saikosaponins might hold the promise for the treatment of COVID-19 based on the following rationale:

1. Saikosaponins exhibit immunomodulatory and anti-inflammatory activities. Saikosaponin A dose-dependently inhibits the production of several inflammatory mediators ROS, TNF- $\alpha$ , COX-2, iNOS, and interleukins (IL-6, IL-8, and IL-10) which are responsible for the cytokine storm of severe COVID-19 patients [1]. Saikosaponin D could exhibit an anti-proliferative effect in activated T-lymphocyte, in part via suppression of the nucleotide-binding oligomerization domain 2 (NOD2)/NF- $\kappa$ B, NF-AT, and AP-1 MAPK signaling, which plays a role in the severity and mortality of COVID-19 [2].
2. Saikosaponins exhibited antiviral activities against several types of viruses in experimental studies. Saikosaponin A inhibited influenza A virus and reduced lung immunopathology. Saikosaponin B demonstrated in-vitro antiviral activity against HCoV-229E by inhibiting the viral attachment to cells in a dose-dependent manner, blocking the viral penetration into cells, and interfering with the early stage of viral replication, such as virus absorption and penetration [3]. Saikosaponin D inhibits the autophagic activity of Enterovirus A71.
3. A molecular docking study demonstrated that Saikosaponin A has a high affinity to bind to a target receptor of the SARS-CoV-2, ACE II receptor [4].

In conclusion, we believe that Saikosaponins are candidate

treatment for COVID-19 owing to their anti-inflammatory, immunomodulatory, and antiviral activities. We recommend future well-designed randomized controlled trials to evaluate the safety and efficacy of Saikosaponins in patients with COVID-19.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.mehy.2020.109782>.

## References

- [1] Yuan B, Yang R, Ma Y, Zhou S, Zhang X, Liu Y. A systematic review of the active saikosaponins and extracts isolated from radix bupleuri and their applications. *Pharm Biol* 2017;55:620–35. <https://doi.org/10.1080/13880209.2016.1262433>.
- [2] Yang H, Chen X, Jiang C, He K, Hu Y. Antiviral and immunoregulatory role against PCV2 in vivo of Chinese herbal medicinal ingredients. *J Vet Res* 2017;61:405–10. <https://doi.org/10.1515/jvetres-2017-0062>.
- [3] Cheng P-W, Ng L-T, Chiang L-C, Lin C-C. Antiviral effects of saikosaponins on human coronavirus 229E in vitro. *Clin Exp Pharmacol Physiol* 2006;33:612–6. <https://doi.org/10.1111/j.1440-1681.2006.04415.x>.
- [4] Yan Y-M, Shen X, Cao Y-K, Zhang J-J, Wang Y, Cheng Y-X, et al. Discovery of anti-2019-nCoV agents from Chinese patent drugs via docking screening. Preprints 2020. <https://doi.org/10.20944/preprints202002.0254.v1>.

Eshak I. Bahbah<sup>a</sup>, Ahmed Negida<sup>b,c,d,\*</sup>, Mohamed Salah Nabet<sup>e</sup>

<sup>a</sup> School of Medicine, Al-Azhar University, Damietta, Egypt

<sup>b</sup> School of Pharmacy and Biological Sciences, University of Portsmouth, UK

<sup>c</sup> School of Medicine, Zagazig University, Sharkia, Egypt

<sup>d</sup> Zagazig University Hospitals, Zagazig University, Sharkia, Egypt

<sup>e</sup> Department of Pharmaceutics and Industrial Pharmacy, School of

Pharmacy, Zagazig University, Sharkia, Egypt

E-mail address: [ahmed01251@medicine.zu.edu.eg](mailto:ahmed01251@medicine.zu.edu.eg) (A. Negida).

\* Corresponding author at: Zagazig University Hospitals, Zagazig University, Sharkia 44523, Egypt.